FORM PTO-1390 U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Rev. 1-98)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY 'S DOCKET NUMBER **JAB-1487**

U S APPLICATION NO. (If known, see 37 CFR 1.5)

09/980452

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/04746	May 23, 2000	June 2, 1999

TITLE OF INVENTION

AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES

APPLICANT(S) FOR DO/EO/US :

Kristof Van Emelen and Marcel Frans Leopold De Bruyn

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.

2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.

3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).

6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.

8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).

9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

13. ☒ A FIRST preliminary amendment.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.

14. ☐ A substitute specification.

15. ☐ A change of power of attorney and/or address letter.

16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR 1 5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/980452	PCT/EP00/04746	JAB-1487

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... $1070.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....$930.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO..... $790.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... $720.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... $98.00

CALCULATIONS PTO USE ONLY

ENTER APPROPRIATE BASIC FEE AMOUNT =				$ 930.00	
Surcharge of $130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	10 - 20 =	0	x $18.00	$	
Independent claims	1 - 3=	0	$84.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $270.00	$	
TOTAL OF ABOVE CALCULATIONS =				$930.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			+	$	
SUBTOTAL =				$930.00	
Processing fee of $130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)) .				$	
TOTAL NATIONAL FEE =				$930.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +				$ 40.00	
TOTAL FEES ENCLOSED =				$970.00	
				Amount to be refunded:	$
				charged:	$

a. ☐ A check in the amount of $_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 10-0750/JAB-1487/ECC in the amount of $970.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-0750/JAB-1487/ECC. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Philip S. Johnson, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
USA

Signature

Ellen Ciambrone Coletti
Reg. No. 34,140
Attorney for Applicants

Docket No. JAB-1487

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Kristof Van Emelen et al.
Serial No.	:	
Filed	:	
Title	:	AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES
Art Unit	:	
Examiner	:	

Honorable Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

In the Specification:

Please add the following paragraph at page 1, between the Title and line 4:

-- Cross Reference to Related Applications

This application is the national stage filing of PCT Application No. PCT/EP00/04746, filed May 23, 2000 which claims priority from EPO Application No. 99201747.5, filed June 2, 1999. --

In the Claims:

Please amend the claims as follows:

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in claim 1.

8. A process for preparing a pharmaceutical composition wherein a therapeutically active amount of a compound as claimed in claim 1 is intimately mixed with a pharmaceutically acceptable carrier.

Please cancel claim 9 and replace with new claim 11.

-- 11. (New) A method of treating conditions involving an impaired relaxation of the fundus comprising administering to a subject in need thereof an effective amount of a compound of claim 1. --

REMARKS/ARGUMENTS

Consideration of the captioned application in view of the foregoing amendments is requested.

The specification has been amended to refer to the priority application.

Claims 7 and 8, have been amended. European style use claim 9 has been canceled and replaced with new claim 11. Support for claim 11 can be found throughout the specification for example at page 11. Claims 1-8 and 11 are pending in this application.

Enclosed herewith are copies of the International Search Report, the references cited in the search report and a completed form PTO 1449.

Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: _____
Ellen Ciambrone Coletti
Reg. No. 34,140

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
Dated: November 30, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Please add the following paragraph at page 1, between the Title and line 4:

-- Cross Reference to Related Applications

This application is the national stage filing of PCT Application No. PCT/EP00/04746, filed May 23, 2000 which claims priority from EPO Application No. 99201747.5, filed June 2, 1999. --

In the Claims:

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in [any of claims] claim 1 [to 6].

8. A process for preparing a pharmaceutical composition [as claimed in claim 7] wherein a therapeutically active amount of a compound as claimed in [any of claims] claim 1 [to 6] is intimately mixed with a pharmaceutically acceptable carrier.

Please cancel claim 9 and replace with new claim 11.

-- 11. (New) A method of treating conditions involving an impaired relaxation of the fundus comprising administering to a subject in need thereof an effective amount of a compound of claim 1. --

AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES

The present invention is concerned with novel aminoalkylchromane compounds having fundic relaxation properties. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.

Structurally related aminomethylchromane derivatives are disclosed in US-5,541,199 as selective autoreceptor agonists useful as antipsychotic agents. Other structurally related aminomethylchroman derivatives having affinity for cerebral 5-hydroxytryptamine receptors of the 5-HT_1 type and therefore suitable for the treatment of disorders of the central nervous system are disclosed in US-5,137,901.

EP-0,546,388, published on 16 June 1993, discloses structurally related amino-methylchroman derivatives having affinity for cerebral 5-hydroxytryptamine receptors of the 5-HT_1 type and for dopamine receptors of the D_2-type. EP-0,628,310, published on 14 December 1994, encompasses the use of the same aminomethylchroman derivatives for the inhibition of HIV-protease.

DE-2,400,094, published on 18 July 1974, discloses 1-[1-[2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl]-4-piperidyl-2-benzimidazolinones possessing blood pressure lowering activity.

DE-2,852,945, published on 26 June 1980, discloses benzodioaxanylhydroxyethyl-piperidylimidazolidinones having antihypertensive activity.

EP-0,004,358, published on 3 October 1979, discloses *N*-oxacycloalkylalkylpiperidines useful as antidepressants and psychostimulants.

EP-0,048,218, published on 24 March 1982, discloses *N*-oxides of *N*-oxacycloalkyl-alkylpiperidines having antidepressant activity.

WO-93/17017, published on 2 September 1993, discloses [(benzodioxane, benzofuran or benzopyran)alkylamino]alkyl-substituted guanidine as selective vasoconstrictors useful to treat conditions related to vasodilatation such as, e.g., migraine, cluster headache and headache associated with vascular disorders.

WO-95/053837, published on 23 February 1995, encompasses dihydrobenzopyran-pyrimidine derivatives also having vasoconstrictive activity.

Other structurally related aminomethylchroman derivatives are disclosed in WO-97/28157, published on 7 August 1997, as α_2-adrenergic receptor antagonists useful in the treatment of degenerative neurological conditions.

The compounds of the present invention differ from the cited art-known compounds structurally, by the nature of the R^5 substituent, and pharmacologically by the fact that, unexpectedly, these compounds have fundic relaxation properties. Furthermore, the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity.

During the consumption of a meal the fundus, *i.e.* the proximal part of the stomach, relaxes and provides a "reservoir" function. Patients having an impaired adaptive relaxation of the fundus upon food ingestion have been shown to be hypersensitive to gastric distension and display dyspeptic symptoms. Therefore, it is believed that compounds which are able to normalize an impaired fundic relaxation are useful to relieve patients suffering from said dyspeptic symptoms.

The present invention concerns compounds of formula (I)



(I),

a stereochemically isomeric form thereof, an *N*-oxide form thereof, a pharmaceutically acceptable acid addition salt thereof, or a quaternary ammonium salt thereof, wherein

Alk^1 is C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonylC_{1-4}alkyl, carbonyl, carbonylC_{1-4}alkyl, or C_{1-6}alkanediyl optionally substituted with hydroxy, halo, amino, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyloxy, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

Alk^2 is C_{1-4}alkylcarbonylC_{1-4}alkyl; C_{1-6}alkanediyl substituted with hydroxy, halo, amino, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy; C_{3-8}cycloalkanediyl optionally substituted with halo, hydroxy, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy,

C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

$-Z^1-Z^2-$ is a bivalent radical of formula

$-O-CH(R^4)-CH_2-$ (a-1),
$-O-CH(R^4)-CH_2-O-$ (a-2),
$-O-CH(R^4)-CH_2-S-$ (a-3),
$-O-CH(R^4)-CH_2-CH_2-$ (a-4),
$-O-CH(R^4)-CH_2-CH_2-CH_2-$ (a-5),
$-O-C(R^4)=CH-$ (a-6),
$-O-C(R^4)=CH-CH_2-$ (a-7),
$-O-C(R^4)=CH-CH_2-CH_2-$ (a-8), or
$-O-CH(R^4)-CH=CH-$ (a-9),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy;

R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}alkenyl, C_{1-6}alkyloxy, trihalomethyl, trihalomethoxy, halo, hydroxy, cyano, nitro, amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxy, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy; or

when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical of formula

$-CH_2-CH_2-CH_2-$ (b-1), $-O-CH_2-CH_2-$ (b-6),
$-CH_2-CH_2-CH_2-CH_2-$ (b-2), $-O-CH_2-CH_2-O-$ (b-7),
$-CH_2-CH_2-CH_2-CH_2-CH_2-$ (b-3), $-O-CH_2-CH_2-CH_2-$ (b-8),
$-CH=CH-CH=CH-$ (b-4), $-O-CH_2-CH_2-CH_2-CH_2-$ (b-9),
$-O-CH_2-O-$ (b-5),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy, C_{1-4}alkyl or CH_2OH;

R^4 is hydrogen, C_{1-6}alkyl, phenylmethyl, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyl, C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or a direct bond when the bivalent radical $-Z^1-Z^2-$ is of formula (a-6), (a-7) or (a-8);

R^6 is hydrogen, C_{1-6}alkyl, C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonyl, phenylmethyl, C_{1-4}alkylaminocarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyl, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

R^5 is a radical of formula



(c-1) (c-2) (c-3) (c-4) (c-5)

wherein n is 1 or 2;

p^1 is 0, and p^2 is 1 or 2; or p^1 is 1 or 2, and p^2 is 0;

X is oxygen, sulfur, NR^9 or $CHNO_2$;

Y is oxygen or sulfur;

R^7 is hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl;

R^8 is C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl;

R^9 is cyano, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkyloxycarbonyl or aminocarbonyl;

R^{10} is hydrogen or C_{1-6}alkyl;

or R^9 and R^{10} taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, or morpholinyl group, optionally substituted with C_{1-4}alkyl or C_{1-4}alkyloxy; and

Q is a bivalent radical of formula

$-CH_2-CH_2-$	(d-1),	$-CO-CH_2-$	(d-6),
$-CH_2-CH_2-CH_2-$	(d-2),	$-(CH_2)_2-CO-$	(d-7),
$-CH_2-CH_2-CH_2-CH_2-$	(d-3),	$-CO-(CH_2)_2-$	(d-8),
$-CH=CH-$	(d-4),	$-CO-CH_2-CO-$	(d-9),
$-CH_2-CO-$	(d-5),	$-CH_2-CO-CH_2-$	(d-10),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C_{1-4}alkyl, hydroxy or phenyl, or

Q is a bivalent radical of formula



(d-11) , or (d-12) .

As used in the foregoing definitions halo is generic to fluoro, chloro, bromo and iodo; C_{1-4}alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methyl-

ethyl, 2-methylpropyl and the like; C_{1-6}alkyl is meant to include C_{1-4}alkyl and the higher homologues thereof having 5 or 6 carbon atoms, such as, for example, 2-methylbutyl, pentyl, hexyl and the like; C_{3-6}cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; C_{3-6}alkenyl defines straight and branched chain unsaturated hydrocarbon radicals having from 3 to 6 carbon atoms, such as propenyl, butenyl, pentenyl or hexenyl; C_{1-2}alkanediyl defines methylene or 1,2-ethanediyl; C_{1-3}alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 1 to 3 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, and the branched isomers thereof; C_{1-5}alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 1 to 5 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, and the branched isomers thereof; C_{1-6}alkanediyl includes C_{1-5}alkanediyl and the higher homologues thereof having 6 carbon atoms such as, for example, 1,6-hexanediyl and the like. The term "CO" refers to a carbonyl group.

Some examples of the R^5 moiety are :



The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said

double bond. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.

In compounds of formula (I) wherein the bivalent radical $-Z^1-Z^2-$ is of formula (a-6), (a-7) or (a-8) the substituent R^4 is a direct bond to the $-Alk^1-NR^6-Alk^2-R^5$ moiety.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (*i.e.* ethanedioic), malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

Quaternary ammonium salts of compounds of formula (I) as used herein defines which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary ammonium salt has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be made using ion exchange resin columns.

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

The *N*-oxide forms of the compounds of formula (I), which may be prepared in art-known manners, are meant to comprise those compounds of formula (I) wherein a nitrogen atom is oxidized to the *N*-oxide.

Interesting compounds are those compounds of formula (I) wherein one or more of the following restrictions apply :

a) the bivalent radical $-Z^1-Z^2-$ is of formula (a-1), or (a-6); or

b) the bivalent radical $-Z^1-Z^2-$ is of formula (a-2), (a-3), (a-4), or (a-9); in particular the bivalent radical $-Z^1-Z^2-$ is of formula (a-3) or (a-4); or

c) the bivalent radical $-Z^1-Z^2-$ is of formula (a-4);

d) R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, hydroxy or halo;

e) R^4 is hydrogen;

f) Alk^1 is C_{1-2}alkanediyl optionally substituted with hydroxy, in particular Alk^1 is $-CH_2-$;

g) Alk^2 is C_{1-3}alkanediyl substituted with hydroxy, in particular Alk^2 is $-CH_2-CHOH-CH_2-$; and/or

h) R^6 is hydrogen of phenylmethyl.

Particular compounds of formula (I) are those compounds of formula (I) wherein the bivalent radical $-Z^1-Z^2-$ is of formula $-CH_2-CH_2-$ (a-4).

Preferred compounds are those compounds of formula (I) wherein R^5 is a radical of formula (c-1) wherein X is oxygen, and Q is a radical of formula (d-2) or (d-5).

More preferred compounds are those compounds of formula (I) wherein R^4 is hydrogen; Alk^1 is $-CH_2-$; Alk^2 is $-CH_2-CHOH-CH_2-$; R^6 is hydrogen; R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2).

Other more preferred compounds are those compounds of formula (I) wherein R^4 is hydrogen; Alk^1 is $-CH_2-$; Alk^2 is $-CH_2-CHOH-CH_2-$; R^6 is hydrogen; R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-5).

Still other preferred compounds are those compounds of formula (I) wherein R^4 is hydrogen; Alk^1 is $-CHOH-CH_2-$; Alk^2 is $-CH_2-CHOH-CH_2-$; R^6 is hydrogen; R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2).

Most preferred compound is
1-[3-[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]-2-hydroxypropyl]-2,4-imidazolidinedione; a stereoisomeric form or a pharmaceutically acceptable acid addition salt thereof.

The compounds of the present invention can generally be prepared by alkylating an

intermediate of formula (III) with an intermediate of formula (II), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo, iodo, or in some instances W may also be a sulfonyloxy group, e.g. methanesulfonyloxy, benzenesulfonyloxy, trifluoromethanesulfonyloxy and the like reactive leaving groups. The reaction can be performed in a reaction-inert solvent such as, for example, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base such as, for example, sodium carbonate, potassium carbonate, calciumoxide or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out in an autoclave at an increased pressure.



(II) (III) (I)

Compounds of formula (I) can also be prepared by reductively alkylating an intermediate of formula (IV), wherein $Alk^{1'}$ represents a direct bond or C_{1-5}alkanediyl, following art-known reductive alkylation procedures with an intermediate of formula (III).



(IV) (III) (I)

Said reductive alkylation can be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of a reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. To enhance the rate of the

reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Alternatively, compounds of formula (I) can also be prepared by reacting an acid chloride of formula (V), wherein $Alk^{1'}$ represents C_{1-5}alkanediyl or a direct bond, with an intermediate of formula (III) under suitable reaction conditions.



(V) (III) (I)

Said reaction can be performed under hydrogenation conditions with hydrogen gas in the presence of a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal, in a suitable solvent such as, for example, ethyl acetate, and in the presence of magnesiumoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g. thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Compounds of formula (I-a), defined as compounds of formula (I) wherein Alk^2 represents $-CH_2-CHOH-CH_2-$, can be prepared by reacting intermediates of formula (VI) with intermediates of formula (VII) in a reaction-inert solvent, such as methanol, and optionally in the presence of an organic base, such as triethyl amine.



(VI) (VII) (I-a)

The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions. For instance, compounds of formula (I) wherein R^6 is phenylmethyl can be converted to the corresponding compounds of formula (I) wherein R^6 is hydrogen by art-known debenzylation procedures. Said debenzylation can be performed following art-known procedures such as catalytic hydrogenation using appropriate catalysts, e.g. platinum on charcoal, palladium on charcoal, in appropriate solvents such as methanol, ethanol, 2-propanol, diethyl ether, tetrahydrofuran, and the like. Furthermore, compounds of formula (I) wherein R^6 is hydrogen may be alkylated using art-known procedures such as, e.g. reductive *N*-alkylation with a suitable aldehyde or ketone.

The compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarbo-peroxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzene-carboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, a number of intermediates of formula (II) or (V) may be prepared according to art-known methodologies described in WO-93/17017 and WO-95/053837.

Compounds of formula (I) and some of the intermediates may have one or more stereogenic centers in their structure, present in a R or a S configuration, such as, e.g. the carbon atom bearing the R^4 substituent, and the carbon atom linked to the $-Alk^1-NR^6-Alk^2-R^5$ moiety.

The compounds of formula (I) as prepared in the hereinabove described processes may be synthesized in the form of racemic mixtures of enantiomers which can be separated

from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable salts and stereoisomeric forms thereof possess favourable fundic relaxation properties as evidenced in pharmacological example C-1, the "Gastric tone measured by an electronic barostat in conscious dogs"-test.

Furthermore, the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity as can be demonstrated in pharmacological example C.2 "Vasoconstrictive activity on basilar artery". Vasconstrictor activity can cause undesirable side-effects such as coronary effects which can induce chest pain.

In view of the capability of the compounds of the present invention to relax the fundus, the subject compounds are useful to treat conditions related to a hampered or impaired relaxation of the fundus such as, e.g. dyspepsia, early satiety, bloating and anorexia.

Dyspepsia is described as a motility disorder. Symptoms can be caused by a delayed gastric emptying or by impaired relaxation of the fundus to food ingestion. Warm-blooded animals, including humans, (generally called herein patients) suffering from dyspeptic symptoms as a result of delayed gastric emptying usually have a normal fundic relaxation and can be relieved of their dyspeptic symptoms by administering a prokinetic agent such as, e.g. cisapride. Patients can have dyspeptic symptoms without having a disturbed gastric emptying. Their dyspeptic symptoms may result from a hypercontracted fundus or hypersensitivity resulting in a diminished compliance and abnormalities in the adaptive fundic relaxation. A hypercontracted fundus results in a diminished compliance of the stomach. The "compliance of the stomach" can be

expressed as the ratio of the volume of the stomach over the pressure exerted by the stomach wall. The compliance of the stomach relates to the gastric tone, which is the result of the tonic contraction of muscle fibers of the proximal stomach. This proximal part of the stomach, by exerting a regulated tonic contraction (gastric tone), accomplishes the reservoir function of the stomach.

Patients suffering from early satiety cannot finish a normal meal since they feel saturated before they are able to finish said normal meal. Normally when a subject starts eating, the stomach will show an adaptive relaxation, *i.e.* the stomach will relax to accept the food that is ingested. This adaptive relaxation is not possible when the compliance of the stomach is hampered which results in an impaired relaxation of the fundus.

In view of the utility of the compounds of formula (I), it follows that the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from impaired relaxation of the fundus to food ingestion. Consequently a method of treatment is provided for relieving patients suffering from conditions, such as, for example, dyspepsia, early satiety, bloating and anorexia.

Hence, the use of a compound of formula (I) as medicine is provided, and in particular the use of a compound of formula (I) for the manufacture of a medicine for treating conditions involving an impaired relaxation of the fundus to food ingestion. Both prophylactic and therapeutic treatment are envisaged.

The symptoms of impaired fundic relaxation may also arise due to the intake of chemical substances, e.g. Selective Seretonine Re-uptake Inhibitors (SSRI's), such as fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups,

elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

For oral administration, the pharmaceutical compositions may take the form of solid dose forms, for example, tablets (both swallowable-only and chewable forms), capsules or gelcaps, prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting

agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art.

Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means, optionally with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methylcellulose, hydroxypropyl methylcellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

Pharmaceutically acceptable sweeteners comprise preferably at least one intense sweetener such as saccharin, sodium or calcium saccharin, aspartame, acesulfame potassium, sodium cyclamate, alitame, a dihydrochalcone sweetener, monellin, stevioside or sucralose (4,1',6'-trichloro-4,1',6'-trideoxy*galacto*sucrose), preferably saccharin, sodium or calcium saccharin, and optionally a bulk sweetener such as sorbitol, mannitol, fructose, sucrose, maltose, isomalt, glucose, hydrogenated glucose syrup, xylitol, caramel or honey.

Intense sweeteners are conveniently employed in low concentrations. For example, in the case of sodium saccharin, the concentration may range from 0.04% to 0.1% (w/v) based on the total volume of the final formulation, and preferably is about 0.06% in the low-dosage formulations and about 0.08% in the high-dosage ones. The bulk sweetener can effectively be used in larger quantities ranging from about 10% to about 35%, preferably from about 10% to 15% (w/v).

The pharmaceutically acceptable flavours which can mask the bitter tasting ingredients in the low-dosage formulations are preferably fruit flavours such as cherry, raspberry, black currant or strawberry flavour. A combination of two flavours may yield very good results. In the high-dosage formulations stronger flavours may be required such as Caramel Chocolate flavour, Mint Cool flavour, Fantasy flavour and the like pharmaceutically acceptable strong flavours. Each flavour may be present in the final composition in a concentration ranging from 0.05% to 1% (w/v). Combinations of said strong flavours are advantageously used. Preferably a flavour is used that does not undergo any change or loss of taste and colour under the acidic conditions of the formulation.

The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example as a sparingly soluble salt.

The compounds of the invention may be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example by bolus injection or continuous intravenous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as isotonizing, suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water before use.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration the compounds of the invention may be used, for example, as a liquid spray, as a powder or in the form of drops.

The formulations of the present invention may optionally include an anti-flatulent, such as simethicone, alpha-D-galactosidase and the like.

In general it is contemplated that a therapeutically effective amount would be from about 0.001 mg/kg to about 2 mg/kg body weight, preferably from about 0.02 mg/kg to about 0.5 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.

Experimental part

In the procedures described hereinafter the following abbreviations were used : "ACN" stands for acetonitrile and "DCM" stands for dichloromethane.

For some chemicals the chemical formula was used, e.g. CH_2Cl_2 for dichloromethane, CH_3OH for methanol, NH_3 for ammonia, HCl for hydrochloric acid, and NaOH for sodium hydroxide.

In those cases the stereochemically isomeric form which was first isolated is designated as "A", the second as "B", the third one as "C" and the fourth one as "D", without further reference to the actual stereochemical configuration.

A. Preparation of the intermediates

Example A.1

A reaction solution of 1-(2-propenyl)-2,4-imidazolidinedione (0.036 mol) and 3-chlorobenzenecarboperoxoic acid (0.043 mol, 70.75%) in DCM (25 ml) was stirred for 2 hours at room temperature. An aqueous solution of bisulfite was added (to remove excess 3-chlorobenzenecarboperoxoic acid) and the mixture was stirred for 10 minutes. Na_2CO_3 was added and this mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated, yielding 5 g (89%) of (±)-1-(oxiranylmethyl)-2,4-imidazolidinedione (interm. 1).

Example A.2

a) A solution of 2-hydroxypyrimidine hydrochloride (1:1) (0.075 mol) in methanol (150 ml) was stirred for 30 minutes and then added to a solution of sodium carbonate (0.075 mol) in methanol (20 ml). The mixture was stirred and refluxed for 15 minutes, and cooled to 55°C. A solution of *N,N*-bis(phenylmethyl)oxiranmethanamine (0.075 mol) in toluene (160 ml) was added dropwise and the reaction mixture was stirred at 50°C overnight. Water (75 ml) was added and the mixture was stirred at 55°C for 15 minutes. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_3OH/CH_2Cl_2 97/3). The pure fractions were collected and the solvent was evaporated, yielding 11.8 g (45%) of (±)-1-[3-[bis(phenylmethyl)amino]-2-hydroxypropyl]-2(1*H*)pyrimidinone (interm. 2).

b) A solution of intermediate (2) (0.034 mol) in methanol (500 ml) was hydrogenated with palladium on activated carbon as a catalyst in the presence of thiophene. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/(CH_3OH/NH_3)$ 95/5). The pure fractions were collected and the solvent was evaporated, yielding 6.15 g (70%) of tetrahydro-1-[2-hydroxy-3-[(phenylmethyl)amino]propyl]-2(1*H*)pyrimidinone (interm. 3).

B. Preparation of the final compounds

Example B.1

3,4-Dihydro-*N*-(phenylmethyl)-2*H*-1-benzopyran-2-methanamine (0.032 mol) in methanol (100 ml) was stirred at room temperature. A solution of intermediate (1) (0.032 mol) in methanol (50 ml) was added dropwise and the resulting reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2/(CH_3OH/NH_3) 99/1). The desired fractions were collected and the solvent was evaporated, yielding 3.5g (27%) of (±)-1-[3-[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl](phenylmethyl)-amino]-2-hydroxypropyl]-2,4-imidazolidinedione (comp. 3).

Example B.2

A mixture of 3,4-dihydro-2*H*-1-benzopyran-2-carboxaldehyde, (0.023 mol) and intermediate (3) (0.023 mol) in methanol (250 ml) was hydrogenated with palladium on activated carbon (10%) as a catalyst in the presence of thiophene. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH_2Cl_2/CH_3OH 99/1). The pure fractions were collected and the solvent was evaporated, yielding 5.9 g (62%) of (±)-1-[3-[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl](phenylmethyl)amino]-2-hydroxypropyl]tetrahydro-2(1*H*)pyrimidinone (comp. 1).

Example B.3

A mixture of compound (3) (0.0086 mol) in methanol (100 ml) was hydrogenated at 25°C with palladium on activated carbon (1 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in ACN and converted into the hydrochloric acid salt (1:1) with HCl/2-propanol. The precipitate was filtered off and dried, yielding 0.49 g of (±)-1-[3-[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]- 2-hydroxypropyl]-2,4-imidazolidinedione monohydrochloride (comp. 4).

Example B.4

a) A solution of 2-hydroxypyrimidine (0.16 mol) in methanol (300 ml) was stirred at room temperature for 30 minutes. A solution of Na_2CO_3 (0.16 mol) in methanol (40 ml) was added. The mixture was stirred and refluxed for 15 minutes and cooled to 55°C. A solution of *N*,*N*-bis(phenylmethyl)-2-oxiranemethanamine (0.16 mol) in toluene (320 ml) was added dropwise. The mixture was stirred at 50°C overnight. Water (150 ml) was added. The mixture was stirred at 55°C for 15 minutes. The organic layer

was separated, washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH_2Cl_2/CH_3OH 97/3). The pure fractions were collected and the solvent was evaporated, yielding 26.55g of (±)-1-[3-[bis(phenylmethyl)amino]-2-hydroxypropyl]-2(1*H*)pyrimidinone (intermediate 4).

b) A mixture of intermediate (4) (0.073 mol) in HCl/2-propanol (20 ml) and CH_3OH (250 ml) was hydrogenated with Pd/C 10% (2 g) as a catalyst. After uptake of hydrogen (3 equivalents), the catalyst was filtered off and the filtrate was evaporated. The residue was separated into its enantiomers by HPLC (eluent : hexane/EtOH 50/50; Chiralpak AD 1000 Å 20 µm). The pure fractions were collected and the solvent was evaporated, yielding 4 g of (A)-tetrahydro-1-[2-hydroxy-3-[(phenylmethyl)amino]propyl]-2(1*H*)-pyrimidinone (intermediate 5).

c) A mixture of [S-(R*,R*)]-3,4-dihydro-2-oxiranyl-2*H*-1-benzopyran (0.006 mol) and intermediate (5) (0.006 mol) in ethanol (25 ml) was stirred and refluxed for 2 hours. The solvent was evaporated and the residue was purified by HPLC (eluent : hexane/ethanol 70/30; Chiralcel OJ 20 µm). The pure fractions were collected and the solvent was evaporated, yielding 1.7 g of [S(A)]-1-[3-[[2-(3,4-dihydro-2*H*-1-benzopyran-2-yl)-2-hydroxy ethyl](phenylmethyl)amino]-2-hydroxypropyl]tetrahydro-2(1*H*)-pyrimidinone (intermediate 6).

d) A mixture of intermediate (6) (0.004 mol) in CH_3OH (100 ml) was hydrogenated with Pd/C 10% (0.5 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off. The reaction mixture was converted into the hydrochloric acid salt (1:1) with HCl/2-propanol. DIPE was added. The precipitate was filtered off and dried, yielding 0.69 g of [S(A)]-1-[3-[[2-(3,4-dihydro-2*H*-1-benzopyran-2-yl)-2-hydroxy ethyl]amino]-2-hydroxypropyl]tetrahydro-2(1*H*)-pyrimidinone monohydrochloride dihydrate (mp. 138°C) (compound 15).



compound 15

Table F-1 and F-2 list the compounds that were prepared according to one of the above Examples and table F.3 lists both the experimental (column heading "exp.") and theoretical (column heading "theor.") elemental analysis values for carbon, hydrogen

and nitrogen of some of the compounds as prepared in the experimental part hereinabove.

Table F-1



Co No.	Ex. No.	R^6	$-Alk^2-R^5$	Physical data (mp. in °C)
1	B.2	$-CH_2-C_6H_5$		-
2	B.3	H		.HCl (1:2)
3	B.1	$-CH_2-C_6H_5$		-
4	B.3	H		.HCl (1:1)
5	B.3	H		(A); .HCl (1:2)
6	B.3	H		(B); .HCl (1:1)
7	B.3	H		(C); .HCl (1:2)
8	B.3	H		(D); .HCl (1:1) .H_2O (1:1)
13	B.1	$-CH_2-C_6H_5$		(R); .HCl (1:1)

Co No.	Ex. No.	R^6	$-Alk^2-R^5$	Physical data (mp. in °C)
14	B.3	H		(R); .HCl (1:1); mp. 241°C; $[\alpha]_D^{20}$ = -75.62°, c= 4.95 mg/ml in CH_3OH

$.C_2H_2O_4$ stands for the ethanedioate salt

Table F-2



Co No.	Ex. No.	R^6	$-Alk^2-R^5$	Physical data (mp. in °C)
9	B.1	$-CH_2-C_6H_5$		.HCl (1:1)
10	B.3	H		.HCl (1:1)
11	B.2	$-CH_2-C_6H_5$		-
12	B.3	H		-

Table F.3 :

Co. No.	Carbon		Hydrogen		Nitrogen	
	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
2	53.30	52.05	7.11	6.94	11.04	10.71
4	52.82	54.01	5.95	6.23	11.34	11.81
5	53.29	52.04	7.60	6.94	10.32	10.71
6	53.94	57.38	7.34	7.36	11.06	11.81
7	52.85	52.04	7.90	6.94	10.15	10.71
8	53.22	54.61	7.65	7.55	10.87	11.24

Co. No.	Carbon		Hydrogen		Nitrogen	
	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
10	53.52	54.01	6.14	6.23	11.63	11.81
12	57.44	57.38	7.31	7.36	11.61	11.81

C. Pharmacological examples

C.1. Gastric tone measured by an electronic barostat in conscious dogs

Gastric tone cannot be measured by manometric methods. Therefore an electronic barostat was used. This allows the study of the physiological pattern and regulation of gastric tone in conscious dogs and the influence of test-compounds on this tone.

The barostat consists of an air injection system which is connected by a double-lumen 14-French polyvinyl tube to an ultrathin flaccid polyethylene bag (maximal volume: ± 700 ml). Variations in gastric tone were measured by recording changes in the volume of air within an intragastric bag, maintained at a constant pressure. The barostat maintains a constant pressure (preselected) within a flaccid air-filled bag introduced into the stomach, changing the volume of air within the bag by an electronic feedback system.

Thus, the barostat measures gastric motor activity (contraction or relaxation) as changes in intragastric volume (decrease or increase resp.) at a constant intragastric pressure. The barostat consists of a strain gauge linked by an electronic relay to an air injection-aspiration system. Both the strain gauge and the injection system are connected by means of double-lumen polyvinyl tube to an ultrathin polyethylene bag. A dial in the barostat allows selection of the pressure level to be maintained within the intragastric bag.

Female beagle dogs, weighing 7-17 kg, were trained to stand quietly in Pavlov frames. They were implanted with a gastric cannula under general anaesthesia and aseptic precautions. After a median laparotomy, an incision was made through the gastric wall in longitudinal direction between the greater and the lesser curve, 2 cm above the nerves of Latarjet. The cannula was secured to the gastric wall by means of a double purse string suture and brought out via a stub wound at the left quadrant of the hypochondrium. Dogs were allowed a recovery period of two weeks.

At the beginning of the experiment, the cannula was opened in order to remove any gastric juice or food remnants. If necessary, the stomach was cleansed with 40 to 50 ml lukewarm water. The ultrathin bag of the barostat was positioned into the fundus of the

stomach through the gastric cannula. In order to ensure easy unfolding of the intragastric bag during the experiment, a volume of 300-400 ml was injected twice into the bag.

When during a stabilisation period of maximum 90 minutes, the gastric volume is stable during 15 minutes at a constanct pressure of 6 mmHg (about 0.81 kPa), the test compound was administered subcutaneously (S.C.), or intraduodenally (I.D.). Test compounds were screened, *i.e.* changes in gastric volume were measured, usually at 0.63 mg/kg. Other doses and routes were tested if a test compound was shown to be active during the screening procedure. Table C-1 summarizes the mean maximal change in volume on relaxation of the fundus, during the 1 hour observation period after S.C. or I.D. administration of the test compound (0.63 mg/kg).

Table C-1 :

Co. No.	Route	Maximum change in volume (ml)	Co. No.	Route	Maximum change in volume (ml)
5	S.C.	41	14	I.D.	144
6	S.C.	146	14	S.C.	90
7	S.C.	34	15	I.D.	5

C.2 Vasoconstrictive activity on basilar artery

Segments of basilar arteries taken from pigs (anaesthetised with sodium pentobarbital) were mounted for recording of isometric tension in organ baths. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37°C and gassed with a mixture of 95% O_2 - 5% CO_2. The preparations were stretched until a stable basal tension of 2 grams was obtained.

The preparations were made to constrict with serotonin ($3x10^{-7}$ M). The response to the addition of serotonin was measured and subsequently the serotonin was washed away. This procedure was repeated until stable responses were obtained. Subsequently the test compound was administered to the organ bath and the constriction of the preparation was measured. This constrictive response was expressed as a percentage of the response to serotonin as measured previously.

The ED_{50}-value (molar concentration) is defined as the concentration at which a test compound causes 50% of the constrictive response obtained with serotonin. Said ED_{50}-values are estimated from experiments on three different preparations.

Claims

1. A compound of formula (I)



(I),

a stereochemically isomeric form thereof, an *N*-oxide form thereof, a pharmaceutically acceptable acid addition salt thereof, or a quaternary ammonium salt thereof, wherein

Alk^1 is C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonylC_{1-4}alkyl, carbonyl, carbonylC_{1-4}alkyl, or C_{1-6}alkanediyl optionally substituted with hydroxy, halo, amino, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyloxy, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

Alk^2 is C_{1-4}alkylcarbonylC_{1-4}alkyl; C_{1-6}alkanediyl substituted with hydroxy, halo, amino, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy; C_{3-8}cycloalkanediyl optionally substituted with halo, hydroxy, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

$-Z^1-Z^2-$ is a bivalent radical of formula

$-O-CH(R^4)-CH_2-$	(a-1),
$-O-CH(R^4)-CH_2-O-$	(a-2),
$-O-CH(R^4)-CH_2-S-$	(a-3),
$-O-CH(R^4)-CH_2-CH_2-$	(a-4),
$-O-CH(R^4)-CH_2-CH_2-CH_2-$	(a-5),
$-O-C(R^4)=CH-$	(a-6),
$-O-C(R^4)=CH-CH_2-$	(a-7),
$-O-C(R^4)=CH-CH_2-CH_2-$	(a-8), or
$-O-CH(R^4)-CH=CH-$	(a-9),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy;

R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}alkenyl, C_{1-6}alkyloxy, trihalomethyl, trihalomethoxy, halo, hydroxy,

cyano, nitro, amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxy, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-4}alkylcarbonyloxy-C_{1-4}alkyloxycarbonyloxy, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxy-carbonyloxy; or

when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical of formula

$-CH_2-CH_2-CH_2-$	(b-1),	$-O-CH_2-CH_2-$	(b-6),
$-CH_2-CH_2-CH_2-CH_2-$	(b-2),	$-O-CH_2-CH_2-O-$	(b-7),
$-CH_2-CH_2-CH_2-CH_2-CH_2-$	(b-3),	$-O-CH_2-CH_2-CH_2-$	(b-8),
$-CH=CH-CH=CH-$	(b-4),	$-O-CH_2-CH_2-CH_2-CH_2-$	(b-9),
$-O-CH_2-O-$	(b-5),		

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy, C_{1-4}alkyl or CH_2OH;

R^4 is hydrogen, C_{1-6}alkyl, phenylmethyl, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyl, C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy, or a direct bond when the bivalent radical $-Z^1-Z^2-$ is of formula (a-6), (a-7) or (a-8);

R^6 is hydrogen, C_{1-6}alkyl, C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonyl, phenylmethyl, C_{1-4}alkylaminocarbonyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkyloxycarbonyl, or C_{3-6}cycloalkylcarbonyloxyC_{1-4}alkyloxycarbonyloxy;

R^5 is a radical of formula



(c-1) (c-2) (c-3) (c-4) (c-5)

wherein n is 1 or 2;

p^1 is 0, and p^2 is 1 or 2; or p^1 is 1 or 2, and p^2 is 0;

X is oxygen, sulfur, NR^9 or $CHNO_2$;

Y is oxygen or sulfur;

R^7 is hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl;

R^8 is C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl;

R^9 is cyano, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkyloxycarbonyl or aminocarbonyl;

R^{10} is hydrogen or C_{1-6}alkyl;

or R^9 and R^{10} taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, or morpholinyl group, optionally substituted with C_{1-4}alkyl or C_{1-4}alkyloxy; and

Q is a bivalent radical of formula

$-CH_2-CH_2-$	(d-1),	$-CO-CH_2-$	(d-6),
$-CH_2-CH_2-CH_2-$	(d-2),	$-(CH_2)_2-CO-$	(d-7),
$-CH_2-CH_2-CH_2-CH_2-$	(d-3),	$-CO-(CH_2)_2-$	(d-8),
$-CH=CH-$	(d-4),	$-CO-CH_2-CO-$	(d-9),
$-CH_2-CO-$	(d-5),	$-CH_2-CO-CH_2-$	(d-10),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C_{1-4}alkyl, hydroxy or phenyl, or

Q is a bivalent radical of formula



, or



.

(d-11) (d-12)

2. A compound as claimed in claim 1 wherein R^5 is a radical of formula (c-1) wherein X is oxygen, and Q is a radical of formula (d-2) or (d-5).

3. A compound as claimed in claim 1 wherein R^4 is hydrogen; Alk^1 is $-CH_2-$, Alk^2 is $-CH_2-CHOH-CH_2-$, R^6 is hydrogen, R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2).

4. A compound according to claim 1 wherein R^4 is hydrogen, Alk^1 is $-CH_2-$, Alk^2 is $-CH_2-CHOH-CH_2-$, R^6 is hydrogen, R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-5).

5. A compound according to claim 1 wherein R^4 is hydrogen; Alk^1 is $-CHOH-CH_2-$; Alk^2 is $-CH_2-CHOH-CH_2-$; R^6 is hydrogen; R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2)

6. A compound according to claim 1 wherein the compound is 1-[3-[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]- 2-hydroxypropyl]-2,4-imidazolidinedione; a stereoisomeric form or a pharmaceutically acceptable acid addition salt thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 6.

8. A process for preparing a pharmaceutical composition as claimed in claim 7 wherein a therapeutically active amount of a compound as claimed in any of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier.

9. A compound as claimed in any of claims 1 to 6 for use as a medicine.

10. A process for preparing a compound of formula (I) wherein

a) an intermediate of formula (II) is alkylated with an intermediate of formula (III) in a reaction-inert solvent and, optionally in the presence of a suitable base,



(II) (III) (I)

b) an intermediate of formula (IV), wherein $Alk^{1'}$ represents a direct bond or C_{1-5}alkanediyl, is reductively alkylated with an intermediate of formula (III);



(IV) (III) (I)

c) an intermediate of formula (VI) is reacted with an intermediate of formula (VII) thus yielding compounds of formula (I-a), defined as compounds of formula (I) wherein Alk^2 represents $-CH_2-CHOH-CH_2-$;



(VI) (VII) (I-a)

in the above reaction schemes the radicals $-Z^1-Z^2-$, R^1, R^2, R^3, R^4, R^5, R^6, Alk^1 and Alk^2 are as defined in claim 1 and W is an appropriate leaving group;

d) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into an acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (12-97)
Approved for use through 9/30/00 OMB 0651-0032
Patent and Trademark Office; U S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	JAB 1487-PCT-USA
First Named Inventor	Kristof Van Emelen
COMPLETE IF KNOWN	
Application Number	/
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 05/23/2000 as United States Application Number or PCT International Application Number PCT/EP00/04746 and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES	NO
99201747.5	EP	06/02/1999	☐	☐	☐
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U S.C. 119(e) of any United States provisional application(s) listed below

Application Number(s)	Filing Date (MM/DD/YYYY)	
		☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (12-97)
Approved for use through 9/30/00 OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☐ Customer Number [ ] → *Place Customer Number Bar Code Label here*
OR
☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Michael Stark	32,495	Myra McCormack	36,602
Steven P. Berman	24,772	Ellen C. Coletti	34,140
Andrea L. Colby	30,194	Mary A. Appollina	34,087

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label [ ] *OR* ☒ Correspondence address below

Name	Philip S. Johnson				
Address	Johnson & Johnson				
Address	One Johnson & Johnson Plaza				
City	New Brunswick	State	NJ	ZIP	08933-7003
Country	USA	Telephone	(732) 524-2359	Fax	(732) 524-2808

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])	Family Name or Surname
Kristof	Van Emelen

Inventor's Signature	[signature]					Date	24 Sept 2001
Residence: City	Sint-Niklaas	State	BEX	Country	Belgium	Citizenship	Belgium
Post Office Address	Janssen Pharmaceutica N.V., Turnhoutseweg 30						
Post Office Address							
City	Beerse	State		ZIP	2340	Country	Belgium

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → [+]

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 3 of 3

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
Marcel Frans Leopold			De Bruyn				
Inventor's Signature						**Date**	24 Sept. 2001
Residence: City	Hoogstraten	**State**	BEX	**Country**	Belgium	**Citizenship**	Belgium
Post Office Address	Janssen Pharmaceutica N.V., Turnhoutseweg 30						
Post Office Address							
City	Beerse	**State**		**ZIP**	2340	**Country**	Belgium

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
Inventor's Signature						**Date**	
Residence: City		**State**		**Country**		**Citizenship**	
Post Office Address							
Post Office Address							
City		**State**		**ZIP**		**Country**	

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
Inventor's Signature						**Date**	
Residence: City		**State**		**Country**		**Citizenship**	
Post Office Address							
Post Office Address							
City		**State**		**ZIP**		**Country**	

Burden Hour Statement: This form is estimated to take 0 4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.